Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease
Introduction. Warfarin remains the preferred oral anticoagulant for the treatment of venous thromboembolism (VTE) in patients with advanced chronic kidney disease (CKD). Although the direct oral anticoagulants (DOACs) have become preferred for treatment of VTE in the general population, patients wit...
Saved in:
| Main Authors: | Tania Ahuja, Kelly Sessa, Cristian Merchan, John Papadopoulos, David Green |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2021/8870015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Plasma levels of direct Xa inhibitors apixaban and rivaroxaban in patients with venous thromboembolism in clinical practice
by: I. Paskaleva, et al.
Published: (2025-05-01) -
ADVANTAGES AND DISADVANTAGES OF WARFARIN AND PRADAXA THERAPY FOR VENOUS THROMBOEMBOLISM
by: B. S. Sukovatykh, et al.
Published: (2018-01-01) -
Temporal Changes in Long‐Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era
by: Kazuhisa Kaneda, et al.
Published: (2024-08-01) -
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
by: Emilie Clay, et al.
Published: (2018-01-01) -
101 Parenteral Bridging Practices and Outcomes in Patients on Warfarin for Mechanical Heart Valves and Venous Thromboembolism
by: Rachel Tang, et al.
Published: (2025-05-01)